[Forced steps for making improvements in severe perioperative haemorrhage]

Severe perioperative bleeding increases perioperative morbidity and mortality. The management of the consequences imposes high burden on the human and financial resources of healthcare providers. Since 2009, there has been a continued worldwide decline in demand for allogenic blood products. This tendency can mainly be attributed to Perioperative Blood Management Program and to new innovative management applying haemostatic factor concentrates, viscoelastic assays and guidelines for treatment of the severe periprocedural bleeding patients. One of the major challenges of our times is still to match blood supply with demand. The new diagnostic and therapeutic modalities for managing the bleeding patients require new financial resources on the one hand and, on the other hand, call for redistribution of the material means provided by the health care system. Achieving interoperability between financial resources allocated to allogenic blood products and factor concentrates, the current state-of-the-art approach for managing the bleeding patient can be used to save blood and the lives of patients simultaneously. Orv Hetil. 2019; 160(6): 203-213.